Supernus Pharmaceuticals, Inc. announced that on February 14, 2024, Tami T. Martin, R.N., Esq., the company?s Senior Vice President, Regulatory Affairs, notified Supernus Pharmaceuticals, Inc. of her retirement from the company effective May 3, 2024. The Company expects Roman Bradel, Ph.D. to join the Company in March 2024 as its Vice President, Regulatory Affairs reporting to Frank Mottola, the Company?s Senior Vice President, Quality, GMP Operations and IT.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.62 USD | +0.46% | +9.95% | -1.11% |
Jul. 01 | Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell 2500 Value Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.11% | 1.57B | |
+7.04% | 73.13B | |
+31.10% | 10.38B | |
+37.94% | 5.16B | |
-17.33% | 4.73B | |
+21.49% | 3.81B | |
+24.92% | 2.26B | |
-36.84% | 1.88B | |
-43.31% | 1.77B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces Executive Changes